Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics

This study is testing a combination of two drugs — ribociclib (a targeted drug that blocks cancer cell division) and belinostat (a drug that changes how cancer cells read their DNA) — in patients with metastatic triple-negative breast cancer or recurrent ovarian cancer, guided by genomic (genetic) testing. **You may be eligible if...** - You have metastatic triple-negative breast cancer (hormone receptor-negative, HER2-negative) that has not responded to prior treatment - Or you have recurrent serous ovarian cancer that cannot be surgically removed - You have measurable disease on imaging (per RECIST 1.1 criteria) - Your organ function meets minimum requirements **You may NOT be eligible if...** - You have hormone receptor-positive or HER2-positive breast cancer - Your cancer has spread to the brain with active symptoms - You have serious heart rhythm problems - You are pregnant or breastfeeding - You have had certain prior treatments that would exclude you Talk to your doctor to see if this trial is right for you.